Tag : Acute Lymphoblastic Leukemia

Latest News

Researchers discover physiological mechanisms underlying pediatric B-ALL

Newsemia
B-cell acute lymphoblastic leukemia (B-ALL) is characterized by the accumulation of abnormal immature B-cell precursors in the bone marrow and is the most common pediatric...
Latest News

Medical Meetings May Be Forever Changed

Newsemia
COVID-19 has caused medical conferences to be canceled this spring. Some regular attendees are expressing relief. Will this disruption lead to lasting changes? Source link...
Latest News

Universal 'One-Size-Fits-All' Cancer Treatment

Newsemia
Andrew Sewell speaks to News-Medical about his breakthrough research, in which he has discovered a new T-Cell that could treat most cancers. Source link...
Latest News

Immunotherapy more effective than chemotherapy for children, young adults with relapsed B-ALL

Newsemia
New findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab is superior to standard chemotherapy for children and young adults with...
Latest News

Chemotherapy can cause drug-resistant mutations in pediatric ALL patients who relapse

Newsemia
Chemotherapy has helped make the most common childhood cancer one of the most curable, but researchers have evidence that the treatment may also prime some...
Pediatrics

Treating the TOTAL patient: clinical trial reduces relapse

Newsemia
A St. Jude Children’s Research Hospital study lowered the rate of relapse for patients with acute lymphoblastic leukemia. Source link...
Pediatrics

Stephan Grupp, MD, PhD, Elected to the National Academy of Medicine

Newsemia
Stephan Grupp, MD, PhD, Chief of the Cell Therapy and Transplant Section in the Division of Oncology and Director of the Cancer Immunotherapy Program at...
Latest News

Editing away cancer and HIV in China: win or lose?

Newsemia
Scientists in China recently edited out the CCR5 gene from a patient with HIV’s stem cells, but the research has sparked ethical debate. Source link...
Latest News

Researchers identify multiple new subtypes of most common childhood cancer

Newsemia
Like cartographers completing a map, investigators have identified multiple new subtypes of the most common childhood cancer–research that will likely improve the diagnosis and treatment...
Pediatrics

Immunotherapy Pioneers Unveil Updated Efficacy Data of Single Infusion of Tisagenlecleucel CAR T-cell Therapy

Newsemia
Physician-scientists from Children’s Hospital of Philadelphia presented updated efficacy and safety data on Kymriah (tisagenlecleucel) –the first-ever FDA-approved personalized CAR T-cell gene immunotherapy for aggressive...
Latest News

FDA permits marketing of ClonoSEQ assay to detect minimal residual disease in blood cancer patients

Newsemia
Today the U.S. Food and Drug Administration permitted marketing of ClonoSEQ assay, a next generation sequencing-based test for minimal residual disease in patients with acute...
Neurology

Double the Risk for Neurotoxicity for Hispanic Kids From ALL Rx

Newsemia
Minority children, notably Hispanics, are more susceptible to developing methotrexate-induced neurotoxicity than non-Hispanic children during treatment for acute lymphoblastic leukemia (ALL). Medscape Medical News Source...
Latest News

FDA accepts Bristol-Myers Squibb’s application for Sprycel for treating pediatric leukemia

Newsemia
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration accepted its supplemental Biologics License Application for Sprycel (dasatinib) in combination with chemotherapy...
Pediatrics

Pioneers at Children's Hospital of Philadelphia Greet European Commission's Approval of Kymriah as Landmark Medical Advance for Young Cancer Patients in Europe

Newsemia
Oncologists from Children’s Hospital of Philadelphia today celebrated a watershed moment in medicine: approval by the European Commission of Kymriah (tisagenlecleucel, formerly CTL019) –the first-ever...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy